Virax Biolabs Group Limited (VRAX)
Market Cap | 10.65M |
Revenue (ttm) | 5,760 |
Net Income (ttm) | -2.60M |
Shares Out | 12.83M |
EPS (ttm) | -0.81 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 73,544 |
Open | 0.820 |
Previous Close | 0.820 |
Day's Range | 0.800 - 0.840 |
52-Week Range | 0.540 - 29.000 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About VRAX
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared the... [Read more]
Financial Performance
Financial StatementsNews

Virax Biolabs' CEO James Foster Issues Letter to Shareholders
LONDON , Feb. 2, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a lette...

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit
Kit Available Now for Distribution LONDON , Jan. 4, 2023 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detecti...

COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States
Kits available Now for Distribution LONDON , Dec. 6, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prev...

Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales
LONDON , Nov. 15, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral disease...

Virax Biolabs Group Limited Announces Closing of $3.8 Million Private Placement
LONDON , Nov. 8, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of ...

Virax Biolabs Group Limited Announces $3.8 Million Private Placement
LONDON , Nov. 4, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of ...

Why Is Virax (VRAX) Stock Up 40% Today?
Small-cap business Virax Biolabs (NASDAQ: VRAX) isn't often in the headlines, but today is a special day for the company. Reportedly, Virax's new rapid testing kit is a triple-threat.

Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit
Kits available in November for Distribution LONDON , Nov. 3, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention...

Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study
LONDON , Oct. 26, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagn...

Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.
Exclusive distribution agreement signed with Cosmos Holdings Inc. (Nasdaq: COSM), providing for exclusive distribution rights in Greece and Cyrus with the opportunity for Cosmos to distribute across E...

Why Is Virax Biolabs (VRAX) Stock Up 40% Today?
Source: Gorodenkoff / Shutterstock.com No question about it — traders are taking notice of Virax Biolabs (NASDAQ: VRAX) today. That's because VRAX stock is soaring 40% this morning after Virax reveal...

Virax BioLabs Presents at H.C. Wainwright's 24th Annual Global Investment Conference
LONDON , Sept. 12, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (NASDAQ: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseas...

Virax Biolabs Group Limited to Present at H.C. Wainwright's 24th Annual Global Investment Conference in New York, NY
LONDON , Sept. 6, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of...

Virax Biolabs Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering
LONDON , Aug. 16, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral disease...

VRAX Stock Alert: Why Is Virax Biolabs Up 120% Today?
Virax Biolabs (NASDAQ: VRAX), a specialist in diagnostic tests, veritably captured the market news cycle today, with its shares skyrocketing 120% before giving up some ground in the afternoon session...

Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears
Monkeypox stocks are rallying amid worries about a shortage of vaccines for the illness in the U.S. Additionally, in recent days, New York state, New York City and San Francisco have issued emergency ...

Virax Biolabs Introduces Monkeypox and Varicella-Zoster Viruses Real-Time PCR Detection Kit
Kits Available in July for Distribution Kits Available in July for Distribution

Virax Biolabs Group Limited Completes Initial Public Offering; Shares Begin Trading Today on NASDAQ Capital Market as VRAX
London, United Kingdom, July 21, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detectio...

Virax Biolabs Group Limited Announces Pricing of $6.75 Million Initial Public Offering
London, United Kingdom, July 20, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detectio...